Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.
about
Therapeutic antibodies, vaccines and antibodyomesHeavy Chain-Only IgG2b Llama Antibody Effects Near-Pan HIV-1 Neutralization by Recognizing a CD4-Induced Epitope That Includes Elements of Coreceptor- and CD4-Binding SitesRecent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal AntibodiesTherapeutic antibodies: current state and future trends--is a paradigm change coming soon?Seasoned adaptive antibody immunity for highly pathogenic pandemic influenza in humans.Engineering antibody-like inhibitors to prevent and treat HIV-1 infection.Bispecific engineered antibody domains (nanoantibodies) that interact noncompetitively with an HIV-1 neutralizing epitope and FcRn.A large human domain antibody library combining heavy and light chain CDR3 diversityEngineered CH2 domains (nanoantibodies).Progress towards recombinant anti-infective antibodies.The smart targeting of nanoparticlesInfluence of novel CD4 binding-defective HIV-1 envelope glycoprotein immunogens on neutralizing antibody and T-cell responses in nonhuman primatesPeptide ligands selected with CD4-induced epitopes on native dualtropic HIV-1 envelope proteins mimic extracellular coreceptor domains and bind to HIV-1 gp120 independently of coreceptor usageAdvancements in Developing Strategies for Sterilizing and Functional HIV Cures.Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virusAbnormal B cell memory subsets dominate HIV-specific responses in infected individuals.Engineered single human CD4 domains as potent HIV-1 inhibitors and components of vaccine immunogensCross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope GlycoproteinsStructure-based identification and neutralization mechanism of tyrosine sulfate mimetics that inhibit HIV-1 entry.Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.Rational design and characterization of the novel, broad and potent bispecific HIV-1 neutralizing antibody iMabm36.Engineered Fc based antibody domains and fragments as novel scaffolds.Molecular structures of trimeric HIV-1 Env in complex with small antibody derivatives.Epitope mapping of M36, a human antibody domain with potent and broad HIV-1 inhibitory activity.Sub-inhibitory concentrations of human α-defensin potentiate neutralizing antibodies against HIV-1 gp41 pre-hairpin intermediates in the presence of serum.Exceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.Engineered antibody variable and constant domains as therapeutic candidates.Germlining of the HIV-1 broadly neutralizing antibody domain m36Antibody engineering for increased potency, breadth and half-life.Monoclonal antibody-based candidate therapeutics against HIV type 1.Improving the CH1-CK heterodimerization and pharmacokinetics of 4Dm2m, a novel potent CD4-antibody fusion protein against HIV-1.Soluble monomeric IgG1 Fc.Bifunctional CD4-DC-SIGN fusion proteins demonstrate enhanced avidity to gp120 and inhibit HIV-1 infection and dissemination.Fusion proteins of HIV-1 envelope glycoprotein gp120 with CD4-induced antibodies showed enhanced binding to CD4 and CD4 binding site antibodies.Cross-neutralizing anti-HIV-1 human single chain variable fragments(scFvs) against CD4 binding site and N332 glycan identified from a recombinant phage library.Pharmacokinetics of engineered human monomeric and dimeric CH2 domainsCharacterization of human IgG repertoires in an acute HIV-1 infectionEngineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.Expression of Human Immunodeficiency Virus Type 1 Neutralizing Antibody Fragments Using Human Vaginal Lactobacillus.
P2860
Q24599662-414E617F-18A2-4533-B44F-0563210606EDQ27679031-EFD0C278-E8B3-4CE9-8BE8-41B3660900BDQ28068946-340C2C89-2453-4779-ABC5-2993093275A3Q28728956-05B6D69D-3BD5-4C65-A4C3-3A93A1CEDB1FQ30403507-8D822B5B-C4B5-4BDE-A134-B1F103577A4EQ30490945-E287C67F-9879-4C9E-A945-5A19AA4A958DQ31082210-A05D0888-3B2E-425A-9FF7-7B946A9A2516Q33514579-99151AA1-46FD-4363-9BDF-77B7CD0B315BQ33521668-EA954FDC-59D2-4456-B358-55EA299C62BDQ33568256-A59AAE57-EA16-45EC-A908-A8235743EA86Q33593665-913B53C5-E0AE-4340-85EF-F09A2E755871Q33614605-7D007012-0A73-4911-97B1-85EB059ECBC0Q33640991-F473F8B8-1EAF-4A52-B62A-EBA5D7B5C5C3Q33654409-54762B5B-30B6-483B-8E5E-75F91C1DB400Q33657941-151E787D-F9D2-4473-BE15-02040AF0611AQ33769283-17C8F9EE-0937-4326-B073-21949B270ED4Q33808304-C7A4B2D4-04AF-426E-B41F-AD70BBE478E3Q33946209-F9BEFE50-D204-482B-8150-8A8265DAD988Q33960361-20E630E8-B5CD-4666-9CAB-1D354035872EQ33972838-0CD3C0D8-16A6-4242-A366-62E3A4DAA66EQ34120088-F117B18B-9D48-4889-A222-FB9A2AFECBF5Q34174815-E7F15DF6-B30D-4C09-B27D-42E76D6FE7E1Q34289289-C28CE74B-4B46-43DD-A404-EF87AF702101Q34522657-B83E9B7A-ED32-48A8-8479-B6E64AE4DA04Q34776841-B9CECF52-1014-4ED8-A3B0-D6776F0B22A4Q34778515-1A6B01AE-B153-46E3-A151-6B31F121FB3BQ35033324-2659BC89-20BC-4982-B736-6B525B2E7C3BQ35044156-E6B0F2FB-F55F-4CDA-B119-AFEE7591B299Q35171173-2437FEE1-732E-46F4-81B9-B5FE31FF69B2Q35575206-9693D337-7578-4F6A-9F9B-122032620A66Q35904501-002EFCA4-AA07-4DE1-8BA8-B9B1CEAE9850Q35952586-9D3B76B1-40FA-4962-AFF8-33728170FB0DQ36003820-31BD4D5E-3B4C-43CE-9917-57F0C4A78EA2Q36172480-036DC3A7-F01D-4922-8275-3809FA8A1005Q36241267-AC89F983-555F-4902-9A90-FB305F8774BFQ36319309-6E8960E8-D7B9-4365-9907-60852D7310F4Q36402802-2BF4DA60-19F9-4B3A-9D30-9CEBE0DCFC82Q36873507-3F0DD3E8-772A-4560-8C7B-88CC53E06FDAQ37132068-149D9176-99F7-4155-8099-7D3F5C59808CQ37346068-E2D26CAF-03BB-41CA-AFAB-6F67CEDAF4A4
P2860
Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers.
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
name
Human domain antibodies to con ...... s-reactive HIV-1 neutralizers.
@ast
Human domain antibodies to con ...... s-reactive HIV-1 neutralizers.
@en
type
label
Human domain antibodies to con ...... s-reactive HIV-1 neutralizers.
@ast
Human domain antibodies to con ...... s-reactive HIV-1 neutralizers.
@en
prefLabel
Human domain antibodies to con ...... s-reactive HIV-1 neutralizers.
@ast
Human domain antibodies to con ...... s-reactive HIV-1 neutralizers.
@en
P2093
P2860
P356
P1476
Human domain antibodies to con ...... s-reactive HIV-1 neutralizers.
@en
P2093
Dimiter S Dimitrov
Weizao Chen
Zhongyu Zhu
P2860
P304
17121-17126
P356
10.1073/PNAS.0805297105
P407
P577
2008-10-28T00:00:00Z